CeQur raises $100M Series E to scale its insulin patch
What's the deal? CeQur, a Horw, Switzerland-based medical device company focused on simplifying insulin delivery, has closed a $100M Series E round in June 2026. The company said the financing reflects commercial momentum and growing demand for its flagship product, CeQur Simplicity — a wearable insulin patch designed to replace multiple daily injections for people with diabetes. Backers were not disclosed.
Why now? The round comes as CeQur reports rising adoption of its Simplicity device across primary care and endocrinology practices, with the company citing better than 85% pharmacy-benefit coverage and an average copay under $45 per month. Demand for simpler, less invasive diabetes management tools has been climbing as the global diabetic population grows and patients seek options that fit more easily into daily life.
What it means. The $100M will go toward scaling commercial operations — expanding the field sales team and supporting an extended 7-day wear version alongside 1-unit and 2-unit dosing options. A raise of this size at the Series E stage suggests CeQur is preparing for a major scale-up push in the mealtime-insulin market, where it competes with insulin pens and pump makers.
Read more: PR Newswire · FinSMEs
